What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?

We delve into all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Wall Street Journal reporter John Carreyrou calls in to talk “Bad Blood,” his forthcoming book about how Theranos rose to a $9 billion valuation and then became a cautionary tale for tech and turtlenecks alike. Then we talk about the courtroom drama that awaits Valeant Pharmaceuticals (or whatever it’s going to be called) and explore how biotech’s latest boom cycle creates risk for mom-and-pop investors. Also there’s a lightening round, which, in retrospect, was perhaps ill-advised.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy